Related Experiment Video
Updated: Apr 16, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
CK1δ in lymphoma: gene expression and mutation analyses and validation of CK1δ kinase activity for therapeutic
B Sophia Winkler1, Franziska Oltmer2, Julia Richter2
1Department of Pathology, Ulm University Hospital Ulm, Germany.
Abstract:
The prognosis of lymphoid neoplasms has improved considerably during the last decades. However, treatment response for some lymphoid neoplasms is still poor, indicating the need for new therapeutic approaches. One promising new strategy is the inhibition of kinases regulating key signal transduction pathways, which are of central importance in tumorigenesis. Kinases of the CK1 family may represent an attractive drug target since CK1 expression and/or activity are associated with the pathogenesis of malignant diseases. Over the last years efforts were taken to develop highly potent and selective CK1-specific inhibitor compounds and their therapeutic potential has now to be proved in pre-clinical trials. Therefore, we analyzed expression and mutational status of CK1δ in several cell lines representing established lymphoma entities, and also measured the mRNA expression level in primary lymphoma tissue as well as in non-neoplastic blood cells. For a selection of lymphoma cell lines we furthermore determined CK1δ kinase activity and demonstrated therapeutic potential of CK1-specific inhibitors as a putative therapeutic option in the treatment of lymphoid neoplasms.
Insights
New kinase inhibitors targeting casein kinase 1 delta (CK1δ) show promise for treating lymphoid neoplasms. This study analyzed CK1δ expression and activity in lymphoma cells, suggesting CK1δ inhibitors as a potential new therapy for these cancers.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Lymphoid neoplasms still have poor treatment responses, necessitating novel therapeutic strategies.
- Kinase inhibition is a promising approach, targeting key signal transduction pathways in tumorigenesis.
- Casein kinase 1 (CK1) family kinases are implicated in malignant disease pathogenesis and are potential drug targets.
Purpose of the Study:
- To investigate the role of CK1δ in lymphoid neoplasms.
- To evaluate the therapeutic potential of CK1-specific inhibitors in treating lymphoid neoplasms.
Main Methods:
- Analysis of CK1δ expression and mutational status in lymphoma cell lines.
- Measurement of CK1δ mRNA levels in primary lymphoma tissues and non-neoplastic blood cells.
- Determination of CK1δ kinase activity in selected lymphoma cell lines.
Main Results:
- CK1δ expression and activity were analyzed in various lymphoma cell lines and primary tissues.
- The study identified potential therapeutic applications for CK1-specific inhibitors.
- Evidence suggests CK1δ inhibitors could be a viable treatment option for lymphoid neoplasms.
Conclusions:
- CK1δ is a relevant target in lymphoid neoplasms.
- CK1-specific inhibitors demonstrate therapeutic potential for lymphoid neoplasms.
- Further pre-clinical trials are warranted to validate CK1δ inhibitors as a novel treatment strategy.
More Related Videos
12:40A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
